The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -115,346 | -124,298 | -26,675 | -22,826 |
| Depreciation expense | 457 | 418 | 370 | 743 |
| Stock-based compensation expense | 1,075 | 632 | 622 | 1,356 |
| Change in fair value of the convertible loan | 101,062 | 105,772 | 14,643 | 548 |
| Non-cash interest expense | 5,555 | 4,829 | 4,341 | 7,398 |
| Impairment expense | - | 5,412 | - | - |
| Change in right-of-use asset | -516 | -594 | -587 | -1,183 |
| Prepaid expenses and other assets | -948 | -194 | -1,018 | 1,173 |
| Accounts payable and accrued liabilities | -352 | -310 | 794 | -818 |
| Accrued compensation | 624 | 348 | 259 | -696 |
| Operating lease liability | -321 | -265 | -257 | -506 |
| Net cash used in operating activities | -5,782 | -6,674 | -4,298 | -14,791 |
| Purchases of property and equipment | 63 | 52 | 242 | 248 |
| Net cash used in investing activities | -63 | -52 | -242 | -248 |
| Proceeds from issuance of term debt, net of issuance costs | - | 0 | 15,000 | 10,000 |
| Payments for taxes related to net share settlement of equity awards | 63 | 0 | 32 | 14 |
| Proceeds from exercise of stock options | 704 | 658 | - | - |
| Net cash provided by financing activities | 641 | 658 | 14,968 | 9,986 |
| Net change in cash, cash equivalents and restricted cash | -5,204 | -6,068 | 10,428 | -5,053 |
| Cash, cash equivalents and restricted cash, beginning of period | 14,078 | 20,146 | 14,771 | - |
| Cash, cash equivalents and restricted cash, end of period | 8,874 | 14,078 | 20,146 | - |
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)